American Lithium
Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

SB-Every BP with a cardiovascular team "needs" Vascepa

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Biobillionair Member Profile
Member Level 
Followed By 98
Posts 14,475
Boards Moderated 0
Alias Born 01/12/13
160x600 placeholder
Gibbs Law Group Files Class Action Lawsuit Alleging Violations of Federal Securities Laws Business Wire - 2/22/2019 6:18:00 PM
Amarin To Report Fourth Quarter and Full Year 2018 Results and Host Conference Call on February 27, 2019 GlobeNewswire Inc. - 2/19/2019 6:00:00 AM
Amarin to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire Inc. - 2/14/2019 6:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2019 4:35:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/8/2019 4:33:41 PM
New REDUCE-IT™ Trial Data Showing the Total Reduction in Ischemic Events Accepted for Presentation at the American Colleg... GlobeNewswire Inc. - 1/23/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/4/2019 4:43:20 PM
Amarin Provides Preliminary 2018 Results and 2019 Outlook GlobeNewswire Inc. - 1/4/2019 4:15:00 PM
Amarin to Present at 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 GlobeNewswire Inc. - 1/2/2019 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/30/2018 6:35:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/30/2018 6:34:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/29/2018 4:08:05 PM
Securities Registration (ads, Immediate) (f-6ef) Edgar (US Regulatory) - 11/29/2018 3:07:20 PM
Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference GlobeNewswire Inc. - 11/28/2018 6:25:36 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/28/2018 5:24:09 PM
Amarin Prices Public Offering of American Depositary Shares GlobeNewswire Inc. - 11/26/2018 8:59:19 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/26/2018 5:32:33 PM
Amarin Announces Proposed Public Offering of American Depositary Shares GlobeNewswire Inc. - 11/26/2018 4:23:58 PM
Amarin to Present at the Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/20/2018 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/14/2018 6:03:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/13/2018 6:18:24 AM
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stro... PR Newswire (US) - 11/11/2018 10:32:00 AM
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stro... GlobeNewswire Inc. - 11/10/2018 3:00:00 PM
Amarin to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire Inc. - 11/8/2018 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/7/2018 4:13:25 PM
Biobillionair Member Level  Tuesday, 02/12/19 08:51:35 AM
Re: SocialBoom post# 175769
Post # of 177248 
SB-Every BP with a cardiovascular team "needs" Vascepa and Amarin. GILD is no different from a PFE, AZN, GSK, MRK or a long list of others.... This doesn't change the fact that Amarin doesn't need to sell and the Vascepa cardiovascular program is NOW GREATLY de-risked. As a drug candidate is de-risked any would be suitor is going to pay closer to retail.

Here's the biggest problem with Amarin M&A: DEFINING RETAIL VALUE OF VASCEPA!!!

I don't think the Vascepa market can be properly defined until at least 2 full years of sales with cardiovascular treatment label for Vascepa.

An M&A will have to contain milestone CVRs based on future sales....Any and ALL of the above BP's can do this deal. Any M&A deal will be either MASSIVE (bidding war) or a long negotiated complex CVR. (long because of the number of interested parties)

My point.....Don't hold your breath on a massive bidding war and huge BO price...I think it will be a complex CVR and likely not anytime soon.

Amarin is going to launch Vascepa into cardiovascular market and perhaps grow into the next GILD.

BB

I do not pump Amarin stock. I am not an Amarin cheerleader. If I see something I don't like I make it known. Patients come first, always!!!
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist